Proteasome inhibitorFDA-approvedSecond-line
Carfilzomib
How it works
Blocks the proteasome, which is involved in protein degradation, preventing cancer cell growth and proliferation.
Cancer types
Leukemia— Multiple myeloma
Efficacy
In clinical trials, around 60% of patients achieved a complete response, with a median overall survival of approximately 17 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Carfilzomib and Sotorasib for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Combining Proteasome Inhibitors in Breast Cancer Cells | Breast Cancer | lab-study | — | Source → |
| Proteasome Inhibitor Shows Promise in Treating Acute Promyelocytic Leukemia | Leukemia | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.